MAPT and frontotemporal dementia: Few trials are targeting sporadic forms of FTD with tau pathology, acting on different mechanisms, including the enhancement of tau clearance, suppression of toxic tau molecules or its production, alteration of mRNA splicing, and augmentation of tau post-translational modifications [266].